{"entity":{"type":"insider","cik":"0001569248","url":"/insider/0001569248","json_url":"/insider/0001569248.json","name":"Burow Kristina","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":59,"n_filings":27,"first":"2013-05-14","last":"2026-07-06","span_basis":"filed_date"},"name_variants":[{"name":"Burow Kristina","source":"filing","n_filings":27,"first_seen":"2013-05-14","last_seen":"2026-07-06"}],"transactions":[{"id":6105030,"accession":"0001012975-26-000622","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001012975-26-000622","line_url":"/filing/0001012975-26-000622#line-2","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Boundless Bio, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"GILLIS STEVEN; CRANDELL KEITH; NELSEN ROBERT; Burow Kristina; BYBEE CLINTON","owner_display_name":"GILLIS STEVEN","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16000.0,"shares_display":"16,000","price_per_share":2.49,"price_display":"2.49","price_state":"stated","total_value":39840.0,"total_display":"39,840.00","total_whole":"39,840","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-01","filed_date":"2026-07-06","scope":"insider"},{"id":5798318,"accession":"0001193125-26-296248","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-296248","line_url":"/filing/0001193125-26-296248","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Scholar Rock Holding Corp","issuer_ticker":"SRRK","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3053.0,"shares_display":"3,053","price_per_share":53.73856102194563,"price_display":"53.74","price_state":"stated","total_value":164063.8268,"total_display":"164,063.83","total_whole":"164,064","shares_owned_after":115605.0,"shares_owned_after_display":"115,605","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-01","filed_date":"2026-07-06","scope":"insider","n_lines":2},{"id":5761337,"accession":"0001012975-26-000564","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-26-000564","line_url":"/filing/0001012975-26-000564#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Kardigan, Inc.","issuer_ticker":"KARD","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"GILLIS STEVEN; CRANDELL KEITH; ARCH Venture Partners XIII, L.P.; ARCH Venture Fund XIII, L.P.; ARCH Venture Partners XIII, LLC; Burow Kristina; NELSEN ROBERT","owner_display_name":"GILLIS STEVEN","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1250000.0,"shares_display":"1,250,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":20000000.0,"total_display":"20,000,000.00","total_whole":"20,000,000","shares_owned_after":15042035.0,"shares_owned_after_display":"15,042,035","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-22","filed_date":"2026-06-24","scope":"insider"},{"id":6017298,"accession":"0001193125-26-204458","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193125-26-204458","line_url":"/filing/0001193125-26-204458#line-3","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Seaport Therapeutics, Inc.","issuer_ticker":"SPTX","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, L.P.; ARCH Venture Partners XII, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT","owner_display_name":"ARCH Venture Fund XII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1100000.0,"shares_display":"1,100,000","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":19800000.0,"total_display":"19,800,000.00","total_whole":"19,800,000","shares_owned_after":6294951.0,"shares_owned_after_display":"6,294,951","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-04","filed_date":"2026-05-04","scope":"insider"},{"id":5832821,"accession":"0001012975-26-000234","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-26-000234","line_url":"/filing/0001012975-26-000234#line-1","is_derivative":false,"issuer_cik":"0001202769","issuer_name":"Lyell Immunopharma, Inc.","issuer_ticker":"LYEL","issuer_name_source":null,"issuer_url":"/issuer/0001202769","owner_cik":null,"owner_name":"GILLIS STEVEN; CRANDELL KEITH; Burow Kristina; BYBEE CLINTON; NELSEN ROBERT; ARCH Venture Partners XIII, L.P.; BERNS PAUL L; ARCH Venture Partners XIII, LLC; ARCH Venture Fund XIII, L.P.","owner_display_name":"GILLIS STEVEN","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":488090.0,"shares_display":"488,090","price_per_share":25.61,"price_display":"25.61","price_state":"stated","total_value":12499984.9,"total_display":"12,499,984.90","total_whole":"12,499,985","shares_owned_after":1426528.0,"shares_owned_after_display":"1,426,528","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-06","filed_date":"2026-03-09","scope":"insider"},{"id":4028044,"accession":"0001012975-25-000681","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-25-000681","line_url":"/filing/0001012975-25-000681#line-1","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1915700.0,"shares_display":"1,915,700","price_per_share":2.61,"price_display":"2.61","price_state":"stated","total_value":4999977.0,"total_display":"4,999,977.00","total_whole":"4,999,977","shares_owned_after":6046907.0,"shares_owned_after_display":"6,046,907","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-27","filed_date":"2025-10-29","scope":"insider"},{"id":4874763,"accession":"0001062993-25-013460","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-25-013460","line_url":"/filing/0001062993-25-013460#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Prime Medicine, Inc.","issuer_ticker":"PRME","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners X, L.P.; ARCH Venture Partners X Overage, L.P.; GILLIS STEVEN; ARCH Venture Partners X, LLC; ARCH Venture Fund X, L.P.; ARCH Venture Fund X Overage, L.P.; Burow Kristina; CRANDELL KEITH","owner_display_name":"ARCH Venture Partners X, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3030300.0,"shares_display":"3,030,300","price_per_share":3.3,"price_display":"3.30","price_state":"stated","total_value":9999990.0,"total_display":"9,999,990.00","total_whole":"9,999,990","shares_owned_after":6230300.0,"shares_owned_after_display":"6,230,300","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-01","filed_date":"2025-08-01","scope":"insider"},{"id":4433847,"accession":"0001415889-25-015005","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-015005","line_url":"/filing/0001415889-25-015005","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Scholar Rock Holding Corp","issuer_ticker":"SRRK","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5400.0,"shares_display":"5,400","price_per_share":29.72418888888889,"price_display":"29.72","price_state":"stated","total_value":160510.62,"total_display":"160,510.62","total_whole":"160,511","shares_owned_after":21071.0,"shares_owned_after_display":"21,071","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-29","filed_date":"2025-05-30","scope":"insider","n_lines":2},{"id":5073040,"accession":"0000950170-25-012590","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-25-012590","line_url":"/filing/0000950170-25-012590","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Metsera, Inc.","issuer_ticker":"MTSR","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2222222.0,"shares_display":"2,222,222","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":39999996.0,"total_display":"39,999,996.00","total_whole":"39,999,996","shares_owned_after":18503128.0,"shares_owned_after_display":"18,503,128","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-02-03","filed_date":"2025-02-03","scope":"insider","n_lines":2},{"id":2544097,"accession":"0000950170-24-041844","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-24-041844","line_url":"/filing/0000950170-24-041844","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Boundless Bio, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":3200000.0,"total_display":"3,200,000.00","total_whole":"3,200,000","shares_owned_after":1181766.0,"shares_owned_after_display":"1,181,766","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-02","filed_date":"2024-04-04","scope":"insider","n_lines":2},{"id":2431765,"accession":"0001062993-24-003738","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-24-003738","line_url":"/filing/0001062993-24-003738#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Prime Medicine, Inc.","issuer_ticker":"PRME","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, LLC; ARCH Venture Fund X, L.P.; Burow Kristina; GILLIS STEVEN; ARCH Venture Fund X Overage, L.P.; ARCH Venture Partners X, L.P.; CRANDELL KEITH","owner_display_name":"ARCH Venture Partners X Overage, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3200000.0,"shares_display":"3,200,000","price_per_share":6.25,"price_display":"6.25","price_state":"stated","total_value":20000000.0,"total_display":"20,000,000.00","total_whole":"20,000,000","shares_owned_after":3200000.0,"shares_owned_after_display":"3,200,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-15","filed_date":"2024-02-20","scope":"insider"},{"id":2997080,"accession":"0001062993-24-002841","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-24-002841","line_url":"/filing/0001062993-24-002841","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Sana Biotechnology, Inc.","issuer_ticker":"SANA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"BYBEE CLINTON; CRANDELL KEITH; GILLIS STEVEN; Burow Kristina","owner_display_name":"BYBEE CLINTON","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1818181.0,"shares_display":"1,818,181","price_per_share":5.5,"price_display":"5.50","price_state":"stated","total_value":9999995.5,"total_display":"9,999,995.50","total_whole":"9,999,996","shares_owned_after":12446022.0,"shares_owned_after_display":"12,446,022","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-08","filed_date":"2024-02-12","scope":"insider","n_lines":3},{"id":8111107,"accession":"0001062993-23-020934","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-23-020934","line_url":"/filing/0001062993-23-020934#line-2","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3357.0,"shares_display":"3,357","price_per_share":11.98,"price_display":"11.98","price_state":"stated","total_value":40216.86,"total_display":"40,216.86","total_whole":"40,217","shares_owned_after":4131207.0,"shares_owned_after_display":"4,131,207","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-14","filed_date":"2023-11-15","scope":"insider"},{"id":8111102,"accession":"0001062993-23-020934","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-23-020934","line_url":"/filing/0001062993-23-020934#line-1","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":31653.0,"shares_display":"31,653","price_per_share":11.75,"price_display":"11.75","price_state":"stated","total_value":371922.75,"total_display":"371,922.75","total_whole":"371,923","shares_owned_after":4127850.0,"shares_owned_after_display":"4,127,850","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-13","filed_date":"2023-11-15","scope":"insider"},{"id":8696657,"accession":"0001062993-23-020714","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001062993-23-020714","line_url":"/filing/0001062993-23-020714","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":17275.0,"shares_display":"17,275","price_per_share":11.489466280752533,"price_display":"11.49","price_state":"stated","total_value":198480.53,"total_display":"198,480.53","total_whole":"198,481","shares_owned_after":4090766.0,"shares_owned_after_display":"4,090,766","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-10","filed_date":"2023-11-13","scope":"insider","n_lines":2},{"id":8696652,"accession":"0001062993-23-020714","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-23-020714","line_url":"/filing/0001062993-23-020714#line-3","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":31079.0,"shares_display":"31,079","price_per_share":10.53,"price_display":"10.53","price_state":"stated","total_value":327261.87,"total_display":"327,261.87","total_whole":"327,262","shares_owned_after":4078922.0,"shares_owned_after_display":"4,078,922","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-09","filed_date":"2023-11-13","scope":"insider"},{"id":8696648,"accession":"0001062993-23-020714","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-23-020714","line_url":"/filing/0001062993-23-020714","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":92251.0,"shares_display":"92,251","price_per_share":11.033170588936706,"price_display":"11.03","price_state":"stated","total_value":1017821.02,"total_display":"1,017,821.02","total_whole":"1,017,821","shares_owned_after":4024719.0,"shares_owned_after_display":"4,024,719","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-08","filed_date":"2023-11-13","scope":"insider","n_lines":2},{"id":8622361,"accession":"0001062993-23-020280","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-23-020280","line_url":"/filing/0001062993-23-020280#line-3","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30192.0,"shares_display":"30,192","price_per_share":11.5,"price_display":"11.50","price_state":"stated","total_value":347208.0,"total_display":"347,208.00","total_whole":"347,208","shares_owned_after":3955592.0,"shares_owned_after_display":"3,955,592","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-07","filed_date":"2023-11-07","scope":"insider"},{"id":8622358,"accession":"0001062993-23-020280","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-23-020280","line_url":"/filing/0001062993-23-020280#line-2","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":43082.0,"shares_display":"43,082","price_per_share":11.55,"price_display":"11.55","price_state":"stated","total_value":497597.1,"total_display":"497,597.10","total_whole":"497,597","shares_owned_after":3925400.0,"shares_owned_after_display":"3,925,400","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-06","filed_date":"2023-11-07","scope":"insider"},{"id":8622356,"accession":"0001062993-23-020280","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-23-020280","line_url":"/filing/0001062993-23-020280#line-1","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":22420.0,"shares_display":"22,420","price_per_share":11.38,"price_display":"11.38","price_state":"stated","total_value":255139.6,"total_display":"255,139.60","total_whole":"255,140","shares_owned_after":3882318.0,"shares_owned_after_display":"3,882,318","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-03","filed_date":"2023-11-07","scope":"insider"},{"id":8532832,"accession":"0001062993-23-018633","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-23-018633","line_url":"/filing/0001062993-23-018633#line-3","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":34560.0,"shares_display":"34,560","price_per_share":13.98,"price_display":"13.98","price_state":"stated","total_value":483148.8,"total_display":"483,148.80","total_whole":"483,149","shares_owned_after":3859898.0,"shares_owned_after_display":"3,859,898","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-29","filed_date":"2023-09-29","scope":"insider"},{"id":8532829,"accession":"0001062993-23-018633","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-23-018633","line_url":"/filing/0001062993-23-018633","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":41951.0,"shares_display":"41,951","price_per_share":13.437089938261305,"price_display":"13.44","price_state":"stated","total_value":563699.36,"total_display":"563,699.36","total_whole":"563,699","shares_owned_after":3825338.0,"shares_owned_after_display":"3,825,338","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-28","filed_date":"2023-09-29","scope":"insider","n_lines":2},{"id":8051260,"accession":"0001062993-23-018548","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-23-018548","line_url":"/filing/0001062993-23-018548#line-2","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":24504.0,"shares_display":"24,504","price_per_share":12.31,"price_display":"12.31","price_state":"stated","total_value":301644.24,"total_display":"301,644.24","total_whole":"301,644","shares_owned_after":3783387.0,"shares_owned_after_display":"3,783,387","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-27","filed_date":"2023-09-27","scope":"insider"},{"id":8051253,"accession":"0001062993-23-018548","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-23-018548","line_url":"/filing/0001062993-23-018548#line-1","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":34000.0,"shares_display":"34,000","price_per_share":11.73,"price_display":"11.73","price_state":"stated","total_value":398820.0,"total_display":"398,820.00","total_whole":"398,820","shares_owned_after":3758883.0,"shares_owned_after_display":"3,758,883","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-26","filed_date":"2023-09-27","scope":"insider"},{"id":8197790,"accession":"0001062993-23-018468","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-23-018468","line_url":"/filing/0001062993-23-018468","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":60740.0,"shares_display":"60,740","price_per_share":11.219360388541324,"price_display":"11.22","price_state":"stated","total_value":681463.95,"total_display":"681,463.95","total_whole":"681,464","shares_owned_after":3694916.0,"shares_owned_after_display":"3,694,916","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-25","filed_date":"2023-09-25","scope":"insider","n_lines":2},{"id":8197783,"accession":"0001062993-23-018468","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-23-018468","line_url":"/filing/0001062993-23-018468#line-1","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40000.0,"shares_display":"40,000","price_per_share":11.14,"price_display":"11.14","price_state":"stated","total_value":445600.0,"total_display":"445,600.00","total_whole":"445,600","shares_owned_after":3664143.0,"shares_owned_after_display":"3,664,143","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-22","filed_date":"2023-09-25","scope":"insider"},{"id":8305855,"accession":"0001610717-23-000291","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001610717-23-000291","line_url":"/filing/0001610717-23-000291#line-7","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1500000.0,"shares_display":"1,500,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":25500000.0,"total_display":"25,500,000.00","total_whole":"25,500,000","shares_owned_after":3624143.0,"shares_owned_after_display":"3,624,143","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-19","filed_date":"2023-09-20","scope":"insider"},{"id":6870829,"accession":"0001628280-22-027125","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001628280-22-027125","line_url":"/filing/0001628280-22-027125","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Prime Medicine, Inc.","issuer_ticker":"PRME","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners X, LLC; GILLIS STEVEN; CRANDELL KEITH; ARCH Venture Partners X, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Fund X Overage, L.P.; Burow Kristina","owner_display_name":"ARCH Venture Partners X, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":800000.0,"shares_display":"800,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":13600000.0,"total_display":"13,600,000.00","total_whole":"13,600,000","shares_owned_after":6128297.0,"shares_owned_after_display":"6,128,297","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-10-24","filed_date":"2022-10-26","scope":"insider","n_lines":2},{"id":4709087,"accession":"0000899243-21-031417","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-031417","line_url":"/filing/0000899243-21-031417#line-2","is_derivative":false,"issuer_cik":"0001219042","issuer_name":"DA32 Life Science Tech Acquisition Corp.","issuer_ticker":"DALS","issuer_name_source":null,"issuer_url":"/issuer/0001219042","owner_cik":null,"owner_name":"GILLIS STEVEN; ARCH Venture Fund XI, L.P.; Burow Kristina; ARCH Venture Partners XI, LLC; ARCH Venture Partners XI, L.P.; NELSEN ROBERT","owner_display_name":"GILLIS STEVEN","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1600000.0,"shares_display":"1,600,000","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":16000000.0,"total_display":"16,000,000.00","total_whole":"16,000,000","shares_owned_after":1600000.0,"shares_owned_after_display":"1,600,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-30","filed_date":"2021-08-03","scope":"insider"},{"id":2083646,"accession":"0001209191-20-051403","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-20-051403","line_url":"/filing/0001209191-20-051403","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Metacrine, Inc.","issuer_ticker":"MTCR","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":230000.0,"shares_display":"230,000","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":2990000.0,"total_display":"2,990,000.00","total_whole":"2,990,000","shares_owned_after":2781769.0,"shares_owned_after_display":"2,781,769","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-09-18","filed_date":"2020-09-22","scope":"insider","n_lines":2},{"id":8121088,"accession":"0001209191-19-053666","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-053666","line_url":"/filing/0001209191-19-053666#line-3","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Vir Biotechnology, Inc.","issuer_ticker":"VIR","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000000.0,"shares_display":"1,000,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":20000000.0,"total_display":"20,000,000.00","total_whole":"20,000,000","shares_owned_after":1000000.0,"shares_owned_after_display":"1,000,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-10-16","filed_date":"2019-10-18","scope":"insider"},{"id":8052526,"accession":"0001012975-19-000197","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001012975-19-000197","line_url":"/filing/0001012975-19-000197","is_derivative":false,"issuer_cik":"0001569248","issuer_name":"Sienna Biopharmaceuticals, Inc.","issuer_ticker":"SNNA","issuer_name_source":null,"issuer_url":"/issuer/0001569248","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2165800.0,"shares_display":"2,165,800","price_per_share":2.5,"price_display":"2.50","price_state":"stated","total_value":5414500.0,"total_display":"5,414,500.00","total_whole":"5,414,500","shares_owned_after":1865800.0,"shares_owned_after_display":"1,865,800","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-22","filed_date":"2019-02-26","scope":"insider","n_lines":3},{"id":6217450,"accession":"0001012975-14-000340","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001012975-14-000340","line_url":"/filing/0001012975-14-000340","is_derivative":false,"issuer_cik":"0001463729","issuer_name":"Receptos, Inc.","issuer_ticker":"RCPT","issuer_name_source":null,"issuer_url":"/issuer/0001463729","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27627.0,"shares_display":"27,627","price_per_share":30.2,"price_display":"30.20","price_state":"stated","total_value":834335.4,"total_display":"834,335.40","total_whole":"834,335","shares_owned_after":1913875.0,"shares_owned_after_display":"1,913,875","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-05-29","filed_date":"2014-05-29","scope":"insider","n_lines":2},{"id":6217438,"accession":"0001012975-14-000340","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001012975-14-000340","line_url":"/filing/0001012975-14-000340","is_derivative":false,"issuer_cik":"0001463729","issuer_name":"Receptos, Inc.","issuer_ticker":"RCPT","issuer_name_source":null,"issuer_url":"/issuer/0001463729","owner_cik":"0001569248","owner_name":"Burow Kristina","owner_display_name":"Burow Kristina","owner_url":"/insider/0001569248","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":67300.0,"shares_display":"67,300","price_per_share":29.41,"price_display":"29.41","price_state":"stated","total_value":1979293.0,"total_display":"1,979,293.00","total_whole":"1,979,293","shares_owned_after":1939895.0,"shares_owned_after_display":"1,939,895","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-05-28","filed_date":"2014-05-29","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":"2014-05-28|6217434","ledger_fault":false,"count":{"value":47,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":31,"open_market":true},{"code":"S","label":"Open-market sale","n":16,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":47},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001727196","name":"Scholar Rock Holding Corp","url":"/issuer/0001727196","role":"Director","n_filings":2,"first_seen":"2025-05-30","last_seen":"2026-07-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001782303","name":"Boundless Bio, Inc.","url":"/issuer/0001782303","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2024-04-04","last_seen":"2026-07-06"},{"type":"issuer","type_label":"ISSUER","cik":"0002123613","name":"Kardigan, Inc.","url":"/issuer/0002123613","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2026-06-24","last_seen":"2026-06-24"},{"type":"issuer","type_label":"ISSUER","cik":"0002042347","name":"Seaport Therapeutics, Inc.","url":"/issuer/0002042347","role":"Ten percent owner","n_filings":1,"first_seen":"2026-05-04","last_seen":"2026-05-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001806952","name":"Lyell Immunopharma, Inc.","url":"/issuer/0001806952","role":"Ten percent owner","n_filings":1,"first_seen":"2026-03-09","last_seen":"2026-03-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001885522","name":"Neumora Therapeutics, Inc.","url":"/issuer/0001885522","role":"Director, Ten percent owner","n_filings":8,"first_seen":"2023-09-20","last_seen":"2025-10-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001894562","name":"Prime Medicine, Inc.","url":"/issuer/0001894562","role":"Ten percent owner","n_filings":3,"first_seen":"2022-10-26","last_seen":"2025-08-01"},{"type":"issuer","type_label":"ISSUER","cik":"0002040807","name":"Metsera, Inc.","url":"/issuer/0002040807","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2025-02-03","last_seen":"2025-02-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001770121","name":"Sana Biotechnology, Inc.","url":"/issuer/0001770121","role":"Ten percent owner","n_filings":1,"first_seen":"2024-02-12","last_seen":"2024-02-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001863294","name":"DA32 Life Science Tech Acquisition Corp.","url":"/issuer/0001863294","role":"Ten percent owner","n_filings":1,"first_seen":"2021-08-03","last_seen":"2021-08-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001634379","name":"Metacrine, Inc.","url":"/issuer/0001634379","role":"Director","n_filings":1,"first_seen":"2020-09-22","last_seen":"2020-09-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001706431","name":"Vir Biotechnology, Inc.","url":"/issuer/0001706431","role":"Director","n_filings":1,"first_seen":"2019-10-18","last_seen":"2019-10-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001656328","name":"Sienna Biopharmaceuticals, Inc.","url":"/issuer/0001656328","role":"Director","n_filings":1,"first_seen":"2019-02-26","last_seen":"2019-02-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001463729","name":"Receptos, Inc.","url":"/issuer/0001463729","role":"Director","n_filings":3,"first_seen":"2013-05-14","last_seen":"2014-05-29"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001569248","retrieved_at":"2026-08-26T19:46:06+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}